Table 5.
Case | Disease | Follow-Up Months | Eye | Initial VFI (%) | Final VFI (%) | Initial MD (dB) | Final MD (dB) | VFI Progression Rate (%/year) 1 |
---|---|---|---|---|---|---|---|---|
OC01 | Optic neuritis | 92 2 | Right | 87 | 97 | −9.54 | −2.61 | +0.9 ± 0.5 |
Left | 71 | 94 | −9.89 | −3.19 | −2.4 ± 0.6 | |||
OC02 | Optic neuritis causing optic nerve atrophy | 97 2 | Right | 99 | 98 | −1.44 | −2.22 | −0.4 ± 0.4 |
Left | 70 | 91 | −11.12 | −7.06 | +0.8 ± 3.5 | |||
OC03 | Bilateral optic neuritis | 16 2 | Right | 48 | 92 | −20.89 | −5.65 | +24.2 ± 28.2 |
Left | 22 | 93 | −27.32 | −3.94 | +61.7 ± 32.9 | |||
OC04 | Optic nerve atrophy (post-meningitis) | 63 2 | Right | 0 | 11 | −31.02 | −25.79 | +76.2 ± 12.3 |
Left | 2 | 91 | −30.22 | −2.4 | +257.0 ± 42.30 | |||
OC05 | Optic nerve atrophy (intracranial hypertension) | 110 2 | Right | 89 | 85 | −0.87 | −7.12 | +1.3 ± 3.8 |
Left | 89 | 88 | 1.15 | −6.72 | +0.6 ± 2.4 | |||
OC06 | Optic nerve atrophy (drug toxicity, etambutol) | 22 2 | Right | 86 | 99 | −4.58 | −0.28 | +4.2 ± 2.4 |
Left | 87 | 99 | −5.67 | −0.1 | +7.1 ± 3.0 | |||
OC07 | Neuroretinitis | 26 2 | Right | 70 | 88 | −11.47 | −2.31 | +6.8 ± 5.4 |
Left | 100 | 100 | 4.06 | 4.18 | +0.1 ± 0.4 | |||
OC08 | Tapetoretinal dystrophy (with superior hemianopia) | 34 2 | Right | 31 | 40 | −26.17 | −20.8 | +2.2 ± 2.9 |
Left | 22 | 48 | −27.64 | −18.42 | +2.5 ± 3.9 | |||
OC09 | Retinitis pigmentosa | 53 3 | Right | 12 | 49 | −27.92 | −19.46 | +0.0 ± 3.7 |
Left | 19 | 49 | −26.88 | −19.85 | +0.4 ± 2.7 | |||
OC10 | Unknown | 14 2 | Right | 5 | 80 | −28.75 | −7.54 | +15.5 ± 4.4 |
Left | 11 | 88 | −27.76 | −8.5 | +10.0 ± 4.9 | |||
OC11 | Unknown (optic nerve injury) | 68 4 | Right | 95 | 98 | −5.13 | −1.9 | +4.1 ± 24.6 |
Left | 90 | 99 | −6.4 | −0.34 | +4.6 ± 22.0 | |||
OC12 | Cone dystrophy | 103 5 | Right | 66 | 70 | −6.99 | −9.96 | +0.1 ± 1.7 |
Left | 71 | 70 | −7.39 | −10.0 | −0.6 ± 1.1 | |||
OC13 | Retinal vascular occlusion | 89 6 | Right | 99 | 99 | −0.22 | −0.51 | +0.6 ± 1.7 |
Left | 31 | 58 | −24.44 | −17.84 | +5.2 ± 2.9 |
1 95% confidence level. 2 Initiation of CoQ10 treatment in month 0. 3 Initiation of CoQ10 treatment in month 47. 4 Initiation of CoQ10 treatment in month 40. 5 Initiation of CoQ10 treatment in month 93. 6 Initiation of CoQ10 treatment in month 57.